1
|
Pande M, Joon A, Brewster AM, Chen WV, Hopper JL, Eng C, Shete S, Casey G, Schumacher F, Lin Y, Harrison TA, White E, Ahsan H, Andrulis IL, Whittemore AS, John EM, Ko Win A, Makalic E, Schmidt DF, Kapuscinski MK, Ochs-Balcom HM, Gallinger S, Jenkins MA, Newcomb PA, Lindor NM, Peters U, Amos CI, Lynch PM. Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. PLoS One 2018; 13:e0196245. [PMID: 29698419 PMCID: PMC5919670 DOI: 10.1371/journal.pone.0196245] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Accepted: 04/09/2018] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Clustering of breast and colorectal cancer has been observed within some families and cannot be explained by chance or known high-risk mutations in major susceptibility genes. Potential shared genetic susceptibility between breast and colorectal cancer, not explained by high-penetrance genes, has been postulated. We hypothesized that yet undiscovered genetic variants predispose to a breast-colorectal cancer phenotype. METHODS To identify variants associated with a breast-colorectal cancer phenotype, we analyzed genome-wide association study (GWAS) data from cases and controls that met the following criteria: cases (n = 985) were women with breast cancer who had one or more first- or second-degree relatives with colorectal cancer, men/women with colorectal cancer who had one or more first- or second-degree relatives with breast cancer, and women diagnosed with both breast and colorectal cancer. Controls (n = 1769), were unrelated, breast and colorectal cancer-free, and age- and sex- frequency-matched to cases. After imputation, 6,220,060 variants were analyzed using the discovery set and variants associated with the breast-colorectal cancer phenotype at P<5.0E-04 (n = 549, at 60 loci) were analyzed for replication (n = 293 cases and 2,103 controls). RESULTS Multiple correlated SNPs in intron 1 of the ROBO1 gene were suggestively associated with the breast-colorectal cancer phenotype in the discovery and replication data (most significant; rs7430339, Pdiscovery = 1.2E-04; rs7429100, Preplication = 2.8E-03). In meta-analysis of the discovery and replication data, the most significant association remained at rs7429100 (P = 1.84E-06). CONCLUSION The results of this exploratory analysis did not find clear evidence for a susceptibility locus with a pleiotropic effect on hereditary breast and colorectal cancer risk, although the suggestive association of genetic variation in the region of ROBO1, a potential tumor suppressor gene, merits further investigation.
Collapse
Affiliation(s)
- Mala Pande
- Department of Gastroenterology, Hepatology and Nutrition, The University of Texas, MD, Anderson Cancer Center, Houston, United States of America
| | - Aron Joon
- Department of Biostatistics, The University of Texas, MD, Anderson Cancer Center, Houston, TX, United States of America
| | - Abenaa M. Brewster
- Department of Clinical Cancer Prevention, The University of Texas, MD, Anderson Cancer Center, Houston, TX, United States of America
| | - Wei V. Chen
- Department of Genetics, The University of Texas, MD, Anderson Cancer Center, Houston, TX, United States of America
| | - John L. Hopper
- Epidemiology and Institute of Health and Environment, The University of Melbourne School of Population and Global Health, Parkville, VIC, Australia
| | - Cathy Eng
- Department of GI Medical Oncology, The University of Texas, MD, Anderson Cancer Center, Houston, TX, United States of America
| | - Sanjay Shete
- Department of Biostatistics, The University of Texas, MD, Anderson Cancer Center, Houston, TX, United States of America
- Department of Epidemiology, The University of Texas, MD, Anderson Cancer Center, Houston, TX, United States of America
| | - Graham Casey
- Center for Public Health Genomics, University of Virginia, Charlottesville, VA, United States of America
| | - Fredrick Schumacher
- Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, United States of America
| | - Yi Lin
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America
| | - Tabitha A. Harrison
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America
| | - Emily White
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America
| | - Habibul Ahsan
- Department of Public Health Sciences, University of Chicago, Chicago, IL, United States of America
| | - Irene L. Andrulis
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Health System, Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
| | - Alice S. Whittemore
- Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, United States of America
| | - Esther M. John
- Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, United States of America
- Department of Epidemiology, Cancer Prevention Institute of California, Fremont, CA, United States of America
| | - Aung Ko Win
- Epidemiology and Institute of Health and Environment, The University of Melbourne School of Population and Global Health, Parkville, VIC, Australia
| | - Enes Makalic
- Epidemiology and Institute of Health and Environment, The University of Melbourne School of Population and Global Health, Parkville, VIC, Australia
| | - Daniel F. Schmidt
- Epidemiology and Institute of Health and Environment, The University of Melbourne School of Population and Global Health, Parkville, VIC, Australia
| | - Miroslaw K. Kapuscinski
- Epidemiology and Institute of Health and Environment, The University of Melbourne School of Population and Global Health, Parkville, VIC, Australia
| | - Heather M. Ochs-Balcom
- Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, United States of America
| | - Steven Gallinger
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Health System, Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
| | - Mark A. Jenkins
- Epidemiology and Institute of Health and Environment, The University of Melbourne School of Population and Global Health, Parkville, VIC, Australia
| | - Polly A. Newcomb
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America
| | - Noralane M. Lindor
- Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, United States of America
| | - Ulrike Peters
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America
| | - Christopher I. Amos
- Department of Community and Family Medicine, Dartmouth College, Lebanon, NH, United States of America
| | - Patrick M. Lynch
- Department of Gastroenterology, Hepatology and Nutrition, The University of Texas, MD, Anderson Cancer Center, Houston, United States of America
| |
Collapse
|
2
|
Abud J, Koehler-Santos P, Ashton-Prolla P, Prolla JC. CHEK2 1100DELC germline mutation: a frequency study in hereditary breast and colon cancer Brazilian families. Arq Gastroenterol 2013; 49:273-8. [PMID: 23329222 DOI: 10.1590/s0004-28032012000400008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/16/2012] [Accepted: 09/12/2012] [Indexed: 01/31/2023]
Abstract
CONTEXT CHEK2 encodes a cell cycle checkpoint kinase that plays an important role in the DNA damage repair pathway, activated mainly by ATM (Ataxia Telangiectasia Mutated) in response to double-stranded DNA breaks. A germline mutation in CHEK2, 1100delC, has been described as a low penetrance allele in a significant number of families with breast and colorectal cancer in certain countries and is also associated with increased risk of contralateral breast cancer in women previously affected by the disease. About 5%-10% of all breast and colorectal cancers are associated with hereditary predisposition and its recognition is of great importance for genetic counseling and cancer risk management. OBJECTIVES Here, we have assessed the frequency of the CHEK2 1100delC mutation in the germline of 59 unrelated Brazilian individuals with clinical criteria for the hereditary breast and colorectal cancer syndrome. METHODS A long-range PCR strategy followed by gene sequencing was used. RESULTS The 1100delC mutation was encountered in the germline of one (1.7%) individual in this high risk cohort. This indicates that the CHEK2 1100delC is not commonly encountered in Brazilian families with multiple diagnoses of breast and colorectal cancer. CONCLUSION These results should be confirmed in a larger series of families and further testing should be undertaken to investigate the molecular mechanisms underlying the hereditary breast and colorectal cancer phenotype.
Collapse
Affiliation(s)
- Jamile Abud
- Programa de Pós-Graduação em Medicina: Ciências Gastroenterológicas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
| | | | | | | | | |
Collapse
|
4
|
Daley D, Lewis S, Platzer P, MacMillen M, Willis J, Elston RC, Markowitz SD, Wiesner GL. Identification of susceptibility genes for cancer in a genome-wide scan: results from the colon neoplasia sibling study. Am J Hum Genet 2008; 82:723-36. [PMID: 18313025 DOI: 10.1016/j.ajhg.2008.01.007] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2007] [Revised: 12/10/2007] [Accepted: 01/07/2008] [Indexed: 01/27/2023] Open
Abstract
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in Americans and is the second leading cause of cancer mortality. Only a minority ( approximately 5%) of familial CRC can be explained by known genetic variants. To identify susceptibility genes for familial colorectal neoplasia, the colon neoplasia sibling study conducted a comprehensive, genome-wide linkage scan of 194 kindreds. Clinical information (histopathology, size and number of polyps, and other primary cancers) was used in conjunction with age at onset and family history for classification of the families into five phenotypic subgroups (severe histopathology, oligopolyposis, young, colon/breast, and multiple cancer) prior to analysis. By expanding the traditional affected-sib-pair design to include unaffected and discordant sib pairs, analytical power and robustness to type I error were increased. Sib-pair linkage statistics and Haseman-Elston regression identified 19 linkage peaks, with interesting results for chromosomes 1p31.1, 15q14-q22, 17p13.3, and 21. At marker D1S1665 (1p31.1), there was strong evidence for linkage in the multiple-cancer subgroup (p = 0.00007). For chromosome 15q14-q22, a linkage peak was identified in the full-sample (p = 0.018), oligopolyposis (p = 0.003), and young (p = 0.0009) phenotypes. This region includes the HMPS/CRAC1 locus associated with hereditary mixed polyposis syndrome (HMPS) in families of Ashkenazi descent. We provide compelling evidence linking this region in families of European descent with oligopolyposis and/or young age at onset (<or=51) phenotypes. We found linkage to BRCA2 in the colon/breast phenotypic subgroup and identified a second locus in the region of D21S1437 segregating with, but distinct from, BRCA2. Linkage to 17p13.3 at marker D17S1308 in the breast/colon subgroup identified HIC1 as a candidate gene. We demonstrated that using clinical information, unaffected siblings, and family history can increase the analytical power of a linkage study.
Collapse
|
7
|
Abstract
While the I1307K APC mutation clearly confers an increased lifetime risk for colorectal cancer, there is a paucity of data on the natural history of colonic neoplasia in symptomatic and asymptomatic mutation carriers. In this study, 51 Jewish I1307K APC mutation carriers were identified in a high-risk familial cancer clinic over a 4-year period, of whom 29 (56.8%) (four males and 25 females) were successfully telephone interviewed for 0.5-5 years (mean 2.4 +/- 1.4) after initial genetic testing. Of these 29 cases, one individual was diagnosed with colon cancer at the age of 45 years, five had adenomatous polyps (mean number of polyps = 1.8), 11 had breast cancer (mean age at diagnosis 49.5 +/- 10.5 years), and 12 were asymptomatic, at the time of the testing. During the follow-up period, new colonic polyps were diagnosed in three mutation carriers, two with previously diagnosed colon cancer and polyps and only one of the asymptomatic mutation carriers, and two additional previously affected patients had new cancer diagnoses: gastric cancer and melanoma. From this descriptive study, it seems that the short-term risk for colonic polyps in I1307K APC mutation is low, primarily affecting patients with previously diagnosed colon tumors.
Collapse
Affiliation(s)
- M Regev
- Susanne Levy-Gertner Oncogenetics Unit, Danek Gertner Institute of Genetics, Tel-Hashomer, Israel
| | | | | | | | | | | |
Collapse
|